amisulpride (Rx)

Brand and Other Names:Barhemsys
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injectable solution

  • 2.5mg/mL (2-mL or 4-mL, single-dose vial)

Postoperative Nausea & Vomiting

Prevention

  • Indicated for prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class
  • 5 mg as a single IV dose at time of anesthesia induction

Treatment

  • Indicated for treatment of PONV in adults who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis
  • 10 mg as a single IV dose in the event of nausea and/or vomiting postoperatively

Dosage Modifications

Renal impairment

  • Mild-to-moderate (≥30 mL/min/1.73 m2): No dosage adjustment necessary
  • Severe (<30 mL/min/1.73 m2): Avoid use; known to be substantially excreted by kidneys and patients with severe renal impairment may have increased systemic exposure and an increased risk of adverse reactions

Safety and efficacy not established

Next:

Interactions

Interaction Checker

and amisulpride

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (26)

            • aripiprazole

              amisulpride, aripiprazole. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.

            • asenapine

              amisulpride, asenapine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.

            • brexpiprazole

              amisulpride, brexpiprazole. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.

            • cariprazine

              amisulpride, cariprazine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.

            • chlorpromazine

              amisulpride, chlorpromazine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.

            • clozapine

              amisulpride, clozapine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndromeIncreases risk of neuroleptic malignant syndrome.

            • dronedarone

              amisulpride and dronedarone both increase QTc interval. Contraindicated.

            • droperidol

              amisulpride, droperidol. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.

            • fluphenazine

              amisulpride, fluphenazine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.

            • haloperidol

              amisulpride, haloperidol. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.

            • iloperidone

              amisulpride, iloperidone. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndromeIncreases risk of neuroleptic malignant syndrome.

            • loxapine

              amisulpride, loxapine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.

            • loxapine inhaled

              amisulpride, loxapine inhaled. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.

            • lumateperone

              amisulpride, lumateperone. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.

            • lurasidone

              amisulpride, lurasidone. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.

            • olanzapine

              amisulpride, olanzapine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndromeIncreases risk of neuroleptic malignant syndrome.

            • paliperidone

              amisulpride, paliperidone. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.

            • perphenazine

              amisulpride, perphenazine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.

            • pimozide

              amisulpride and pimozide both increase QTc interval. Contraindicated.

              amisulpride, pimozide. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.

            • prochlorperazine

              amisulpride, prochlorperazine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.

            • quetiapine

              amisulpride, quetiapine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndromeIncreases risk of neuroleptic malignant syndrome.

            • risperidone

              amisulpride, risperidone. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.

            • thioridazine

              amisulpride and thioridazine both increase QTc interval. Contraindicated.

              amisulpride, thioridazine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.

            • thiothixene

              amisulpride, thiothixene. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.

            • trifluoperazine

              amisulpride, trifluoperazine. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndrome.

            • ziprasidone

              amisulpride, ziprasidone. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Increases risk of neuroleptic malignant syndromeIncreases risk of neuroleptic malignant syndrome.

            Serious - Use Alternative (150)

            • alfuzosin

              amisulpride and alfuzosin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • amantadine

              amisulpride, amantadine. Either decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid use of amisulpride, a dopamine receptor antagonist, with dopamine agonists.

            • amiodarone

              amiodarone and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • apomorphine

              amisulpride, apomorphine. Either decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid use of amisulpride, a dopamine receptor antagonist, with dopamine agonists.

              apomorphine and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • arformoterol

              arformoterol and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • aripiprazole

              aripiprazole and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • arsenic trioxide

              amisulpride and arsenic trioxide both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • artemether

              artemether and amisulpride both increase QTc interval. Avoid or Use Alternate Drug.

            • artemether/lumefantrine

              amisulpride and artemether/lumefantrine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • asenapine

              amisulpride and asenapine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • atomoxetine

              atomoxetine and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • azithromycin

              amisulpride and azithromycin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • bedaquiline

              amisulpride and bedaquiline both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • bromocriptine

              amisulpride, bromocriptine. Either decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid use of amisulpride, a dopamine receptor antagonist, with dopamine agonists.

            • buprenorphine

              amisulpride and buprenorphine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • ceritinib

              ceritinib and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • chloroquine

              chloroquine and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • chlorpromazine

              chlorpromazine and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • ciprofloxacin

              amisulpride and ciprofloxacin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • citalopram

              citalopram and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • clarithromycin

              clarithromycin and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • clozapine

              clozapine and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • crizotinib

              crizotinib and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • dasatinib

              dasatinib and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • degarelix

              degarelix and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • desflurane

              desflurane and amisulpride both increase QTc interval. Avoid or Use Alternate Drug.

              amisulpride and desflurane both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • deutetrabenazine

              deutetrabenazine and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • disopyramide

              amisulpride and disopyramide both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • dofetilide

              amisulpride and dofetilide both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • dolasetron

              amisulpride and dolasetron both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • donepezil

              donepezil and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • droperidol

              amisulpride and droperidol both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • efavirenz

              efavirenz and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • eliglustat

              amisulpride and eliglustat both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • encorafenib

              encorafenib and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • entrectinib

              entrectinib and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • eribulin

              eribulin and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • erythromycin base

              amisulpride and erythromycin base both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • erythromycin ethylsuccinate

              amisulpride and erythromycin ethylsuccinate both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • erythromycin lactobionate

              amisulpride and erythromycin lactobionate both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • erythromycin stearate

              amisulpride and erythromycin stearate both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • escitalopram

              amisulpride and escitalopram both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • fenoldopam

              amisulpride, fenoldopam. Either decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid use of amisulpride, a dopamine receptor antagonist, with dopamine agonists.

            • fexinidazole

              amisulpride and fexinidazole both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • fingolimod

              fingolimod and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • flecainide

              amisulpride and flecainide both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • fluconazole

              amisulpride and fluconazole both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • fluoxetine

              amisulpride and fluoxetine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • fluvoxamine

              amisulpride and fluvoxamine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • formoterol

              amisulpride and formoterol both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • foscarnet

              amisulpride and foscarnet both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • fostemsavir

              amisulpride and fostemsavir both increase QTc interval. Avoid or Use Alternate Drug. QTc prolongation reported with higher than recommended doses of fostemsavir.

            • gemifloxacin

              gemifloxacin and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • gemtuzumab

              amisulpride and gemtuzumab both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • gilteritinib

              amisulpride and gilteritinib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • glasdegib

              amisulpride and glasdegib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • goserelin

              amisulpride and goserelin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • granisetron

              amisulpride and granisetron both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • haloperidol

              amisulpride and haloperidol both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • histrelin

              amisulpride and histrelin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • hydroxychloroquine sulfate

              amisulpride and hydroxychloroquine sulfate both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • hydroxyzine

              amisulpride and hydroxyzine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • ibutilide

              amisulpride and ibutilide both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • iloperidone

              amisulpride and iloperidone both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • indacaterol, inhaled

              amisulpride and indacaterol, inhaled both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • inotuzumab

              amisulpride and inotuzumab both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • isoflurane

              amisulpride and isoflurane both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • itraconazole

              amisulpride and itraconazole both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • ivosidenib

              amisulpride and ivosidenib both decrease QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • lapatinib

              amisulpride and lapatinib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • lefamulin

              amisulpride and lefamulin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • lenvatinib

              amisulpride and lenvatinib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • leuprolide

              amisulpride and leuprolide both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • levalbuterol

              amisulpride and levalbuterol both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • levodopa

              amisulpride, levodopa. Either decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid use of amisulpride, a dopamine receptor antagonist, with dopamine agonists.

            • levodopa inhaled

              amisulpride, levodopa inhaled. Either decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid use of amisulpride, a dopamine receptor antagonist, with dopamine agonists.

            • levofloxacin

              amisulpride and levofloxacin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • levoketoconazole

              amisulpride and levoketoconazole both increase QTc interval. Avoid or Use Alternate Drug.

            • lithium

              amisulpride and lithium both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

              lithium and amisulpride both increase QTc interval. Avoid or Use Alternate Drug.

            • lofexidine

              amisulpride and lofexidine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • loperamide

              amisulpride and loperamide both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • lopinavir

              amisulpride and lopinavir both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • macimorelin

              amisulpride and macimorelin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • maprotiline

              maprotiline and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • mefloquine

              amisulpride and mefloquine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • methadone

              amisulpride and methadone both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • midostaurin

              amisulpride and midostaurin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • mifepristone

              amisulpride and mifepristone both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • mirtazapine

              amisulpride and mirtazapine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • mobocertinib

              amisulpride and mobocertinib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • moxifloxacin

              amisulpride and moxifloxacin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • nilotinib

              amisulpride and nilotinib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • octreotide

              amisulpride and octreotide both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • octreotide (Antidote)

              amisulpride and octreotide (Antidote) both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • ofloxacin

              amisulpride and ofloxacin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • olanzapine

              amisulpride and olanzapine both increase QTc interval. Avoid or Use Alternate Drug. Limited data, including some case reports, suggest that olanzapine may be associated with a significant prolongation of the QTc interval in rare instances

            • olodaterol inhaled

              amisulpride and olodaterol inhaled both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • ondansetron

              amisulpride and ondansetron both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • osilodrostat

              amisulpride and osilodrostat both increase QTc interval. Avoid or Use Alternate Drug. Dose dependent QT prolongation - avoid drugs known to prolong the QT interval

            • osimertinib

              amisulpride and osimertinib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • oxaliplatin

              amisulpride and oxaliplatin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • ozanimod

              amisulpride and ozanimod both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • paliperidone

              amisulpride and paliperidone both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • panobinostat

              amisulpride and panobinostat both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • pasireotide

              amisulpride and pasireotide both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • pazopanib

              amisulpride and pazopanib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • pentamidine

              amisulpride and pentamidine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • perphenazine

              perphenazine and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • pimavanserin

              amisulpride and pimavanserin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • pitolisant

              amisulpride and pitolisant both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • ponesimod

              amisulpride and ponesimod both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • posaconazole

              amisulpride and posaconazole both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • pramipexole

              amisulpride, pramipexole. Either decreases effects of the other by pharmacodynamic antagonism. Contraindicated. Avoid use of amisulpride, a dopamine receptor antagonist, with dopamine agonists.

            • primaquine

              amisulpride and primaquine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • procainamide

              amisulpride and procainamide both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • promethazine

              promethazine and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • propafenone

              amisulpride and propafenone both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • quetiapine

              amisulpride and quetiapine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • quinidine

              quinidine and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • quinine

              amisulpride and quinine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • ranolazine

              amisulpride and ranolazine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • rilpivirine

              amisulpride and rilpivirine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • risperidone

              amisulpride and risperidone both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • romidepsin

              amisulpride and romidepsin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • ropinirole

              amisulpride, ropinirole. Either decreases effects of the other by pharmacodynamic antagonism. Contraindicated. Avoid use of amisulpride, a dopamine receptor antagonist, with dopamine agonists.

            • rotigotine

              amisulpride, rotigotine. Either decreases effects of the other by pharmacodynamic antagonism. Contraindicated. Avoid use of amisulpride, a dopamine receptor antagonist, with dopamine agonists.

            • salmeterol

              amisulpride and salmeterol both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • saquinavir

              amisulpride and saquinavir both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • selpercatinib

              amisulpride and selpercatinib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • sertraline

              amisulpride and sertraline both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • sevoflurane

              amisulpride and sevoflurane both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • siponimod

              amisulpride and siponimod both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • sorafenib

              amisulpride and sorafenib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • sotalol

              amisulpride and sotalol both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • sunitinib

              amisulpride and sunitinib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • tacrolimus

              amisulpride and tacrolimus both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • tetrabenazine

              amisulpride and tetrabenazine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • toremifene

              amisulpride and toremifene both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • trazodone

              trazodone and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • triclabendazole

              amisulpride and triclabendazole both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • triptorelin

              amisulpride and triptorelin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • umeclidinium bromide/vilanterol inhaled

              amisulpride and umeclidinium bromide/vilanterol inhaled both decrease QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • vandetanib

              amisulpride and vandetanib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • vardenafil

              amisulpride and vardenafil both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • vemurafenib

              amisulpride and vemurafenib both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • venlafaxine

              amisulpride and venlafaxine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • vilanterol/fluticasone furoate inhaled

              amisulpride and vilanterol/fluticasone furoate inhaled both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • voclosporin

              amisulpride and voclosporin both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • vorinostat

              amisulpride and vorinostat both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            • ziprasidone

              amisulpride and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.

            Monitor Closely (20)

            • albuterol

              albuterol and amisulpride both increase QTc interval. Use Caution/Monitor.

              amisulpride and albuterol both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.

            • amitriptyline

              amitriptyline and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.

              amisulpride and amitriptyline both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.

            • clofazimine

              amisulpride and clofazimine both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.

            • clomipramine

              clomipramine and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.

            • desipramine

              desipramine and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.

            • doxepin

              doxepin and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.

            • ezogabine

              amisulpride and ezogabine both increase QTc interval. Use Caution/Monitor. Slight and transient QT-prolongation observed, particularly when dose titrated to 1200mg/day. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval.

            • fluphenazine

              fluphenazine and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.

            • gadobenate

              gadobenate and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.

            • imipramine

              imipramine and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.

            • indapamide

              amisulpride and indapamide both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.

            • nortriptyline

              nortriptyline and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.

            • osilodrostat

              osilodrostat and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.

            • phenylephrine PO

              amisulpride increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .

            • prochlorperazine

              prochlorperazine and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.

            • protriptyline

              protriptyline and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.

            • solifenacin

              amisulpride and solifenacin both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.

            • telavancin

              amisulpride and telavancin both increase QTc interval. Modify Therapy/Monitor Closely. ECG monitoring is recommended if coadministered.

            • trifluoperazine

              trifluoperazine and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.

            • trimipramine

              trimipramine and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.

            Minor (0)

              Previous
              Next:

              Adverse Effects

              1-10%

              Prevention of PONV

              • Increased blood prolactin (5%)
              • Chills (4%)
              • Hypokalemia (4%)
              • Procedural hypotension (3%)
              • Abdominal distension (2%)

              Treatment of PONV

              • Infusion site pain (6%)

              Postmarketing Reports

              Blood and lymphatic system disorders: Agranulocytosis

              Cardiac disorders: Bradycardia, torsades de pointes, ventricular tachycardia, prolonged QT by ECG

              General disorders: Neuroleptic malignant syndrome

              Immune system disorders: Angioedema, hypersensitivity, urticaria

              Hepatic disorders: Increased hepatic enzymes

              Nervous system disorders: Agitation, anxiety, dystonia, extrapyramidal disorder, seizure

              Psychiatric disorders: Confusional state, insomnia, somnolence

              Vascular disorders: Hypotension

              Previous
              Next:

              Warnings

              Contraindications

              Hypersensitivity

              Cautions

              QT prolongation

              • May causes dose- and concentration-dependent prolongation of the QT interval
              • Avoid in patients with congenital long QT syndrome and in patients taking droperidol
              • ECG monitoring recommended with preexisting arrhythmias/cardiac conduction disorders, electrolyte abnormalities (eg, hypokalemia, hypomagnesemia), congestive heart failure, and in patients taking other drugs (eg, ondansetron) or with other medical conditions known to prolong the QT interval

              Drug interactions overview

              • Amisulpride inhibits MATE1 and MATE2-K transporters
              • Amisulpride is a substrate for P-gp, BCRP, OCT1, MATE1, and MATE2-K
              • Dopamine agonists
                • Reciprocal antagonism of effects occurs between dopamine agonists (eg, levodopa)
                • Avoid use
              • Drugs prolonging the QT interval
                • Amisulpride causes dose- and concentration-dependent QT prolongation
                • Avoid use with droperidol
                • ECG monitoring recommended if coadministered with other drugs known to prolong QT interval (eg, ondansetron)
              Previous
              Next:

              Pregnancy & Lactation

              Pregnancy

              Insufficient data available regarding use in pregnant women to establish a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes

              Infertility

              • In animal fertility studies, administration of repeated doses of amisulpride over a 10­-day period to female rats resulted in infertility that was reversible

              Lactation

              Based on case reports in published literature, amisulpride is present in human milk at concentrations that are 11- to 20-fold higher than human plasma in patients taking multiple oral doses of amisulpride (200-400 mg/day)

              There are no reports of adverse effects on breastfed children and no information on effects of amisulpride on milk production

              May consider interrupting breastfeeding and pumping and discarding breast milk for 48 hr after administration to minimize drug exposure to a breastfed infant

              Pregnancy Categories

              A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

              B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

              C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

              D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

              X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

              NA: Information not available.

              Previous
              Next:

              Pharmacology

              Mechanism of Action

              Selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist

              D2 receptors are located in the chemoreceptor trigger zone (CTZ) and respond to the dopamine released from the nerve endings

              Activation of CTZ relays stimuli to the vomiting center, which is involved in emesis

              Absorption

              Peak plasma concentration

              • Healthy subjects: 200 ng/mL (5 mg); 451 ng/mL (10 mg)
              • Patients: 58-64 ng/mL (5 mg); 446 ng/mL (10 mg)

              AUC

              • Healthy subjects: 154 ng⋅hr/mL (5 mg); 136 ng⋅hr/mL (10 mg)
              • Patients: 204-260 ng⋅hr/mL (5 mg); 401 ng⋅hr/mL (10 mg)

              Distribution

              Vd: 127-144 L (surgical patients); 171 L (healthy subjects)

              Protein bound: 25-30%

              Metabolism

              No metabolites were detectable in plasma while 4 metabolites were identified in urine and feces

              Each metabolite accounts for <7% of the dose

              In vitro amisulpride is not metabolized by major cytochrome P450 enzymes

              Elimination

              Half-life: ~ 4-5 hr

              Clearance: 20.6 hr (surgical patients); 24.1 L/hr (healthy subjects)

              Renal clearance: 20.5 L/hr (healthy subjects)

              Excretion: Urine (74% [58% unchanged]), feces (23% [20% unchanged])

              Previous
              Next:

              Administration

              IV Compatibilities

              Sterile water for injection

              Dextrose 5% (D5W)

              0.9% NaCl

              Lactated Ringer (LR)

              IV Administration

              Dilution not required

              Infuse over 1-2 min

              May flush IV line before or after administration with sterile water for injection, D5W, LR, or 0.9% NaCl

              Storage

              Protect from light

              Unopened vials: Store at 20-25ºC (68-77ºF)

              Open vials: Administer within 12 hr of removal of the vial from the protective carton

              Previous
              Next:

              Images

              No images available for this drug.
              Previous
              Next:

              Patient Handout

              A Patient Handout is not currently available for this monograph.
              Previous
              Next:

              Formulary

              FormularyPatient Discounts

              Adding plans allows you to compare formulary status to other drugs in the same class.

              To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

              Adding plans allows you to:

              • View the formulary and any restrictions for each plan.
              • Manage and view all your plans together – even plans in different states.
              • Compare formulary status to other drugs in the same class.
              • Access your plan list on any device – mobile or desktop.

              The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

              Tier Description
              1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
              2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
              3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
              4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              NC NOT COVERED – Drugs that are not covered by the plan.
              Code Definition
              PA Prior Authorization
              Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
              QL Quantity Limits
              Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
              ST Step Therapy
              Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
              OR Other Restrictions
              Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
              Additional Offers
              Email to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Email Forms to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Previous
              Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.